Drug Trial Radar · NCT05197049
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
350
Actual
Start
Jan 19, 2022
Primary completion
Jul 4, 2023
Study completion Mar 27, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
Conditions
- Crohn Disease
Interventions
Guselkumab Dose 1Drug
Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
Guselkumab Dose 2Drug
Guselkumab (Dose 2) will be administered by SC injection.
Guselkumab Dose 3Drug
Guselkumab (Dose 3) will be administered by SC injection.
PlaceboDrug
Placebo will be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Clinical Remission at Week 12Time frame: At Week 12
- Percentage of Participants Who Achieved Endoscopic Response at Week 12Time frame: At Week 12
Locations
345 sites in 27 countries. Site status is shown where the registry gives one.
Digestive Health Specialists of the Southeast
Dothan, Alabama
Advanced Gastro P.C
Chandler, Arizona
Reliance Research
Scottsdale, Arizona
Moore Clinical Trials, LLC
Little Rock, Arkansas
Central Arkansas Veterans Healthcare System
Little Rock, Arkansas
Clinnova Research
Anaheim, California
Om Research LLC 1
Lancaster, California
Om Research LLC
Lancaster, California
United Gastroenterologists
Los Alamitos, California
Paul Wallace MD
Los Angeles, California
Digestive System Healthcare
Pasadena, California
Northshore Gastroenterology Research, LLC
San Diego, California
Clinical Applications Laboratories, Inc
San Diego, California
Santa Maria Gastroenterology
Santa Maria, California
Clinical Research of California
Walnut Creek, California
Amel Med LLC Research
Grand Junction, Colorado
Western Connecticut Health Network/Danbury Hospital
Danbury, Connecticut
Gastroenterology Associates of SW Florida
Clearwater, Florida
Pioneer Research Solutions Inc.
Coconut Creek, Florida
Omega Research Consultants
DeBary, Florida
Harmony Medical Research Institute, Inc.
Hialeah, Florida
Central Florida Gastro Research
Kissimmee, Florida
Community Research Foundation, Inc.
Miami, Florida
Gastroenterology Group Of Naples
Naples, Florida
Center for Digestive Health
Orlando, Florida
Central Florida Internists
Orlando, Florida
Synergy Clinical Research
St. Petersburg, Florida
Atlanta Gastroenterology Specialists, PC
Atlanta, Georgia
Agile Clinical Research Trials, LLC
Atlanta, Georgia
Atlanta Center For Gastroenterology
Decatur, Georgia
Gastroenterolgy Associates of Central GA
Macon, Georgia
Gastroenterology Consultants
Roswell, Georgia
USF Asthma, Allergy, Immunology Clinical Research Unit
Boise, Idaho
Grand Teton Research Group, PLLC
Idaho Falls, Idaho
Lemah Creek Clinical Research
Oakbrook Terrace, Illinois
University of Kansas Medical Center
Kansas City, Kansas
BVL Clinical Research
Leawood, Kansas
Cotton O'Neil Digestive Health Center
Topeka, Kansas
Tri-State Gastroenterology Assoc
Crestview Hills, Kentucky
Tandem Clinical Research
Marrero, Louisiana
Showing 40 of 345 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.